yihe chen

yihe chen


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in International Journal of Biological Sciences
Verified
Journal Article
Open access
YCyihe chen
yihe chen
HLHui Lin
Hui Lin
QWQian Wang
Qian Wang
JHJian-Wen Hou
Jian-Wen Hou
ZMZhi-Jie Mao
Zhi-Jie Mao
YLYi-Gang Li
Yi-Gang Li
Silibinin is a traditional medicine and utilized for liver protection with antioxidant, anti-inflammation and anti-apoptosis properties. However, its role in myocardial I/R injury and the mechanism involved is currently unknown. In the present study, Silibinin treatment improves cardiac function and limits infarct size, and subsequently inhibits fibrotic remodeling in mice with myocardial I/R injury. Mechanistically, silibinin reduces cardiomyocytes apoptosis, attenuates mitochondrial impairment and endoplasmic reticulum (ER) stress, alleviates ROS generation, neutrophil infiltration and cytokines release. Consistently, silibinin prevents H9C2 cells from hypoxia/reperfusion-induced cell death, oxidative stress and inflammation in vitro. Furthermore, H9C2 cells treated with silibinin blocks NF-κB signaling activation by inhibiting IKKα phosphorylation, IκBα degradation and p65 NF-κB nuclear translocation during hypoxia/ reperfusion. In addition, silibinin plus BAY 11-7082 (a selected NF-κB inhibitor) do not provide incremental benefits in improving myocytes apoptosis, oxidative stress and inflammation in comparison with NF-κB signaling inhibition only. Thus, silibinin-mediated cardioprotection in myocardial I/R injury is associated with decreased apoptosis, oxidative stress and inflammatory response through deactivation of NF-κB pathway.

28 April 2019 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
ZMZhi-Jie Mao
Zhi-Jie Mao
HLHui Lin
Hui Lin
JHJian-Wen Hou
Jian-Wen Hou
QZQian Zhou
Qian Zhou
QWQian Wang
Qian Wang
YCyihe chen
yihe chen
Aims. Myocardial ischemia/reperfusion (I/R) injury is a leading cause of cardiomyocyte loss and subsequent ventricular dysfunction after restoring the coronary blood flow and contributes to considerable increase in morbidity and mortality. Resveratrol has been declared to confer cardioprotection against in vivo and ex vivo myocardial I/R injury. Here, we have sought to investigate the effects of preconditioning with resveratrol on myocardial I/R damage across the small animal studies. Methods and Results. The MEDLINE, Google Scholar, PubMed, and Cochrane databases were searched for preclinical studies investigating resveratrol vs. vehicle published from the inception to July 2018. Eventually, 10 in vivo and 7 ex vivo studies with 261 animals (130 for resveratrol; 131 for vehicle) were included for meta-analysis. Pooled estimates for primary outcomes demonstrated that pretreatment with resveratrol significantly reduced the infarct size after myocardial I/R injury irrespective of in vivo (weighted mean difference (WMD): -13.42, 95% CI: -16.63 to -10.21, P≤0.001) or ex vivo (WMD: -15.05, 95% CI: -18.23 to -11.86, P≤0.001) studies. Consistently, stratified analysis according to the reperfusion duration, route of administration, or timing regimen of pretreatment all showed the infarct-sparing benefit of resveratrol. Metaregression did not indicate any difference in infarct size based on species, sample size, state, route of administration, reperfusion duration, and timing regimen of pretreatment. Meanwhile, sensitivity analysis also identified the cardioprotection of resveratrol with robust results in spite of significant heterogeneity. Conclusions. Preconditioning with resveratrol appears to prevent the heart from I/R injury in comparison with vehicle, as evidenced by limited infarct size in a preclinical setting. Studies with large animals or randomized controlled trials will add more evidence and provide the rationale for clinical use.

27 June 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
ZMZhi-Jie Mao
Zhi-Jie Mao
HLHui Lin
Hui Lin
FXFang-Yi Xiao
Fang-Yi Xiao
ZHZhouqing Huang
Zhouqing Huang
YCyihe chen
yihe chen
Aims. Myocardial reperfusion damage after severe ischemia was an important issue during a clinical practice. However, the exacted pathogenesis involved remained unclear and also lacks effective interventions. Melatonin was identified to exert protective effects for alleviating the myocardial I/R injury. This meta-analysis was determined to evaluate the efficacy of melatonin treatment against reperfusion insult and further summarize potential molecular and cellular mechanisms. Methods and Results. 15 eligible studies with 211 animals (108 received melatonin and 103 received vehicle) were included after searching the databases of PubMed, MEDLINE, Embase, and Cochrane. Pretreatment with melatonin was associated with a significant lower infarct size in comparison with vehicle in myocardial I/R damage (WMD: -20.45, 95% CI: -25.43 to -15.47, p<0.001; I2=91.4%, p<0.001). Evidence from subgroup analyses and sensitivity analysis indicated the robust and consistent cardioprotective effect of melatonin, while the metaregression also did not unmask any significant interactions between the pooled estimates and covariates (i.e., sample size, state, species, study type, route of administration, and duration of reperfusion, along with timing regimen of pretreatment). Accordingly, melatonin evidently increased EF (WMD: 17.19, 95% CI: 11.08 to 23.29, p<0.001; I2=77.0%, p<0.001) and FS (WMD: 14.18, 95% CI: 11.22 to 17.15, p<0.001; I2=3.5%, p=0.387) in the setting of reperfusion damage. Conclusions. Melatonin preadministration conferred a profound cardioprotection against myocardial I/R injury in preclinical studies.

1 September 2015 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
YCyihe chen
yihe chen
JLJiafeng Lin
Jiafeng Lin

18 January 2022 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
YCyihe chen
yihe chen
LWLiang‐Guo Wang
Liang‐Guo Wang
XZXiao-Dong Zhou
Xiao-Dong Zhou
YFYing Fang
Ying Fang
LSLan Su
Lan Su
FXFangyi Xiao
Fangyi Xiao

1 April 2017 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
YCyihe chen
yihe chen
QWQian Wang
Qian Wang
CLChang-Yi Li
Chang-Yi Li
JHJian-Wen Hou
Jian-Wen Hou
XCXiao-Meng Chen
Xiao-Meng Chen
YLYigang Li
Yigang Li